keyword
https://read.qxmd.com/read/38628935/super-elderly-case-of-acute-lower-limb-ischemia-treated-with-indigo-aspiration-system-in-japan
#1
Shinsuke Kikuchi, Seima Ohira, Tsutomu Doita, Keisuke Kamada, Naoya Kuriyama, Yuya Tamaru, Takamitsu Tatsukawa, Yuri Yoshida, Daiki Uchida, Nobuyoshi Azuma
The Indigo Aspiration System (Penumbra Ltd., Alameda, CA, USA), a catheter-based device intended for the endovascular removal of clots from peripheral arteries and veins, was launched in Japan to treat acute limb ischemia after the cessation of urokinase sales. The initial application of this system in Japan was on a 96-year-old male patient. He was diagnosed with acute lower limb ischemia, which was caused by an embolism from a left common iliac artery aneurysm. The treatment significantly enhanced the perfusion to his left foot...
March 25, 2024: Annals of Vascular Diseases
https://read.qxmd.com/read/38553243/thrombotic-microenvironment-responsive-crosslinking-cyclodextrin-metal-organic-framework-nanocarriers-for-precise-targeting-and-thrombolysis
#2
JOURNAL ARTICLE
Caijie Yuan, Yaxin Ye, Enling Hu, Ruiqi Xie, Bitao Lu, Kun Yu, Weiwei Ding, Wenyi Wang, Guangqian Lan, Fei Lu
Global public health is seriously threatened by thrombotic disorders because of their high rates of mortality and disability. Most thrombolytic agents, especially protein-based pharmaceuticals, have a short half-life in circulation, reducing their effectiveness in thrombolysis. The creation of an intelligent drug delivery system that delivers medication precisely and releases it under regulated conditions at nearby thrombus sites is essential for effective thrombolysis. In this article, we present a unique medication delivery system (MCRUA) that selectively targets platelets and releases drugs by stimulation from the thrombus' microenvironment...
June 15, 2024: Carbohydrate Polymers
https://read.qxmd.com/read/38545120/corrigendum-urokinase-type-plasminogen-activator-and-plasminogen-activator-inhibitor-1-complex-as-a-serum-biomarker-for-covid-19
#3
Tetiana Yatsenko, Ricardo Rios, Tatiane Nogueira, Yousef Salama, Satoshi Takahashi, Yoko Tabe, Toshio Naito, Kazuhisa Takahashi, Koichi Hattori, Beate Heissig
[This corrects the article DOI: 10.3389/fimmu.2023.1299792.].
2024: Frontiers in Immunology
https://read.qxmd.com/read/38542130/the-crosstalk-between-n-formyl-peptide-receptors-and-upar-in-systemic-sclerosis-molecular-mechanisms-pathogenetic-role-and-therapeutic-opportunities
#4
JOURNAL ARTICLE
Filomena Napolitano, Francesca Wanda Rossi, Amato de Paulis, Antonio Lavecchia, Nunzia Montuori
Systemic Sclerosis (SSc) is a heterogeneous autoimmune disease characterized by widespread vasculopathy, the presence of autoantibodies and the progressive fibrosis of skin and visceral organs. There are still many questions about its pathogenesis, particularly related to the complex regulation of the fibrotic process, and to the factors that trigger its onset. Our recent studies supported a key role of N-formyl peptide receptors (FPRs) and their crosstalk with uPAR in the fibrotic phase of the disease. Here, we found that dermal fibroblasts acquire a proliferative phenotype after the activation of FPRs and their interaction with uPAR, leading to both Rac1 and ERK activation, c-Myc phosphorylation and Cyclin D1 upregulation which drive cell cycle progression...
March 9, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38534360/the-roles-of-fibrinolytic-factors-in-bone-destruction-caused-by-inflammation
#5
REVIEW
Yosuke Kanno
Chronic inflammatory diseases, such as rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, Crohn's disease, periodontitis, and carcinoma metastasis frequently result in bone destruction. Pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), IL-6, and IL-17 are known to influence bone loss by promoting the differentiation and activation of osteoclasts. Fibrinolytic factors, such as plasminogen (Plg), plasmin, urokinase-type plasminogen activator (uPA), its receptor (uPAR), tissue-type plasminogen activator (tPA), α2-antiplasmin (α2AP), and plasminogen activator inhibitor-1 (PAI-1) are expressed in osteoclasts and osteoblasts and are considered essential in maintaining bone homeostasis by regulating the functions of both osteoclasts and osteoblasts...
March 15, 2024: Cells
https://read.qxmd.com/read/38532827/biomarkers-of-chronic-inflammation-and-cognitive-decline-a-prospective-observational-study
#6
JOURNAL ARTICLE
Bhavna A Guduguntla, Alexi Vasbinder, Elizabeth Anderson, Tariq U Azam, Pennelope Blakely, Noah J Webster, Richard Gonzalez, Toni Atonucci, Judith L Heidebrink, Bruno Giordani, Laura Zahodne, Benjamin M Hampstead, Kristine J Ajrouch, Salim S Hayek
We sought to determine whether the biomarkers of chronic inflammation predict cognitive decline in a prospective observational study. We measured baseline serum soluble urokinase plasminogen activator receptor (suPAR) and high sensitivity C-reactive protein (hs-CRP) levels in 282 participants of the University of Michigan Memory and Aging Project. Cognitive function was measured using the Montreal Cognitive Assessment (MoCA) and the Clinical Dementia Rating (CDR) scale for up to five time points. SuPAR and hs-CRP levels were not significantly higher in participants with mild cognitive impairment ( n  = 97) or dementia ( n  = 59), compared to those with normal cognitive function ( n  = 126)...
2024: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://read.qxmd.com/read/38476861/prognostic-biomarkers-and-aki-potential-to-enhance-the-identification-of-post-operative-patients-at-risk-of-loss-of-renal-function
#7
REVIEW
Rishabh Singh, James C Watchorn, Alexander Zarbock, Lui G Forni
Acute kidney injury (AKI) is a common complication after surgery and the more complex the surgery, the greater the risk. During surgery, patients are exposed to a combination of factors all of which are associated with the development of AKI. These include hypotension and hypovolaemia, sepsis, systemic inflammation, the use of nephrotoxic agents, tissue injury, the infusion of blood or blood products, ischaemia, oxidative stress and reperfusion injury. Given the risks of AKI, it would seem logical to conclude that early identification of patients at risk of AKI would translate into benefit...
2024: Research and Reports in Urology
https://read.qxmd.com/read/38468249/a-versatile-engineered-extracellular-vesicle-platform-simultaneously-targeting-and-eliminating-senescent-stromal-cells-and-tumor-cells-to-promote-tumor-regression
#8
JOURNAL ARTICLE
Liangzhi Gong, Zhengsheng Chen, Kai Feng, Lei Luo, Juntao Zhang, Ji Yuan, Yajing Ren, Yang Wang, Xianyou Zheng, Qing Li
Chemotherapy is an important therapeutic approach for malignant tumors for it triggers apoptosis of cancer cells. However, chemotherapy also induces senescence of stromal cells in the tumor microenvironment to promote tumor progression. Strategies aimed at killing tumor cells while simultaneously eliminating senescent stromal cells represent an effective approach to cancer treatment. Here, we developed an engineered Src-siRNA delivery system based on small extracellular vesicles (sEVs) to simultaneously eliminate senescent stromal cells and tumor cells for cancer therapy...
March 11, 2024: Journal of Nanobiotechnology
https://read.qxmd.com/read/38451430/mitigation-of-human-iris-angiogenesis-through-upar-lrp-1-interaction-antagonism-in-an-organotypic-ex%C3%A2-vivo-model
#9
JOURNAL ARTICLE
Noemi Anna Pesce, Flavia Plastino, Claudia Reyes-Goya, Jonathan Bernd, Vincenzo Pavone, Massimo Dal Monte, Anders Kvanta, Filippo Locri, Helder André
Rubeosis Iridis (RI) is characterized by an increase in neovascularization and inflammation factors in the iris. During angiogenesis, the urokinase plasminogen activator (uPA) and its receptor (uPAR) play a pivotal role in extracellular matrix remodeling, where uPAR regulates endothelial cell migration and proliferation through assembly with transmembrane receptors. Here, in the context of hypoxia-induced angiogenesis, the uPA/uPAR system blockage was investigated by using UPARANT in a novel ex vivo human iris organotypic angiogenesis assay...
March 15, 2024: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology
https://read.qxmd.com/read/38448612/soluble-urokinase-plasminogen-activator-receptor-supar-in-children-with-obesity-or-type-1-diabetes-as-a-marker-of-endothelial-dysfunction-a-cross-sectional-study
#10
JOURNAL ARTICLE
Eirini Kostopoulou, Dimitra Kalavrizioti, Panagiota Davoulou, Xenophon Sinopidis, Evangelos Papachristou, Dimitrios S Goumenos, Gabriel Dimitriou, Bessie E Spiliotis, Marios Papasotiriou
Pediatric obesity and type 1 diabetes mellitus (T1DM) represent two common chronic diseases associated with chronic inflammation, endothelial dysfunction and long-term complications. The aim of the present study was to assess the possible diagnostic and prognostic value of soluble urokinase plasminogen activator receptor (suPAR), a marker of inflammation and impaired endothelial function, in children with the diseases. In this cross-sectional study, children and adolescents with T1DM (N = 41) or obesity (N = 37), aged < 18 years old, and without proteinuria were included, together with children of similar age and without evident morbidity that served as controls (N = 42)...
March 7, 2024: European Journal of Pediatrics
https://read.qxmd.com/read/38419677/nanomicrosphere-sustained-release-urokinase-systems-with-antioxidant-properties-for-deep-vein-thrombosis-therapy
#11
JOURNAL ARTICLE
Shun Xiao, Xiaozhi Sun, Chong Wang, Jianlie Wu, Kun Zhang, Mingjin Guo, Bing Liu
Deep vein thrombosis (DVT) is a venous return disorder caused by abnormal clotting of blood in deep veins. After thrombosis, most of the thrombus will spread to the deep vein trunk throughout the limb. If DVT is not treated in time, most of them will develop into thrombosis sequelae and even threaten life. Intravenous thrombolytic drugs are the most promising strategy for treating DVT, but current drugs used for thrombolysis suffer from short half-lives and narrow therapeutic indexes. To effectively manage DVT, it is necessary to develop a novel multifunctional drug-loading system to effectively prolong the treatment time and improve the therapeutic efficacy...
February 21, 2024: RSC Advances
https://read.qxmd.com/read/38385539/robotic-stereotactic-radiosurgery-with-cyberknife-brain-metastases-and-fibrinolysis
#12
JOURNAL ARTICLE
Veselin Popov, Vasko Graklanov, Snezhana Stoencheva, Zhanet Grudeva-Popova
OBJECTIVES: Deviations in haemostasis are found in about 50 % of patients with cancer and up to 90% of those with metastatic disease. Many studies investigate the dynamics of the processes of coagulation and fibrinolysis and their role as a predictor of therapeutic response, early relapse, or metastasis risk. BACKGROUND: To investigate the serum levels of urokinase plasminogen activator (uPA) in patients with brain metastases treated with robotic stereotactic radiosurgery (SRS) with CyberKnife...
2024: Bratislavské Lekárske Listy
https://read.qxmd.com/read/38339315/phase-i-ii-trial-of-urokinase-plasminogen-activator-targeted-oncolytic-newcastle-disease-virus-for-canine-intracranial-tumors
#13
JOURNAL ARTICLE
John H Rossmeisl, Jamie N King, John L Robertson, James Weger-Lucarelli, Subbiah Elankumaran
Neurotropic oncolytic viruses are appealing agents to treat brain tumors as they penetrate the blood-brain barrier and induce preferential cytolysis of neoplastic cells. The pathobiological similarities between human and canine brain tumors make immunocompetent dogs with naturally occurring tumors attractive models for the study of oncolytic virotherapies. In this dose-escalation/expansion study, an engineered Lasota NDV strain targeting the urokinase plasminogen activator system (rLAS-uPA) was administered by repetitive intravenous infusions to 20 dogs with intracranial tumors with the objectives of characterizing toxicities, immunologic responses, and neuroradiological anti-tumor effects of the virus for up to 6 months following treatment...
January 29, 2024: Cancers
https://read.qxmd.com/read/38309306/a-microthrombus-driven-fixed-point-cleaved-nanosystem-for-preventing-post-thrombolysis-recurrence-via-inhibiting-ferroptosis
#14
JOURNAL ARTICLE
Mengjuan Sun, Chang Liu, Ji Liu, Jing Wen, Tianjiao Hao, Daquan Chen, Yan Shen
Thrombus-induced cardiovascular diseases threaten human health. Current treatment strategies often rely on urokinase plasminogen activator (uPA) for its efficacy, yet it has such limiting factors as short half-life, lack of thrombus targeting, and systemic side effects leading to unintended bleeding. In addition, thrombolytic interventions can trigger inflammation-induced damage at thrombus sites, which affects endothelial function. To address these challenges, Fer-1/uPA@pep-CREKA-Lipo (Fu@pep-CLipo) has been developed...
February 1, 2024: Journal of Controlled Release
https://read.qxmd.com/read/38241162/minimally-invasive-puncture-combined-with-a-high-frequency-of-urokinase-therapy-improves-outcomes-in-patients-with-hich
#15
JOURNAL ARTICLE
Jianbing Xiong, Yuanbing Chen, Ruolong Wang, Shanshan Hu, Ji Xu, Xiaoye Mo, Xiaogang Li, Yong Zhou, Chaxiang Guan, Jun Huang, Feng Su
Minimally invasive puncture combined with urokinase is widely used in the treatment of hypertensive intracerebral hemorrhage (HICH). However, the appropriate frequency of urokinase following minimally invasive puncture in patients is still unclear. In total, 55 patients were enrolled in this study. According to the frequency of urokinase (10.0 ​× ​104 units) administration, 30 patients received urokinase at Q4h, while the other 25 patients received urokinase at Q8h. In the univariate analysis, preoperative GCS (p ​= ​0...
January 2024: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://read.qxmd.com/read/38236383/urokinase-plasminogen-activator-receptor-an-important-focal-player-in-chronic-subdural-hematoma
#16
JOURNAL ARTICLE
Thorbjørn Søren Rønn Jensen, Markus Harboe Olsen, Giedrius Lelkaitis, Andreas Kjaer, Tina Binderup, Kåre Fugleholm
Chronic subdural hematoma (CSDH) development involves inflammatory, angiogenetic, and fibrinolytic mechanisms, several components of which are now unraveled through intensive research. The urokinase plasminogen activator receptor (uPAR) is part of the plasminogen activator system and possesses inflammatory, angiogenetic, and fibrinolytic capabilities. As a first, this study aims to identify uPAR in the hematoma fluid, hematoma membrane, dura mater, and systemic blood from patients with CSDH and, if present, to investigate if the uPAR level at the time of surgery may be a predictor for later developing recurrent CSDH...
January 18, 2024: Inflammation
https://read.qxmd.com/read/38220339/dual-targeting-fucoidan-based-microvesicle-for-arterial-thrombolysis-and-re-occlusion-inhibition
#17
JOURNAL ARTICLE
Zhechang Chen, Caijie Yuan, Yaxin Ye, Bitao Lu, Enling Hu, Fei Lu, Kun Yu, Ruiqi Xie, Guangqian Lan
Arterial thrombosis is a critical thrombotic disease that poses a significant threat to human health. However, the existing clinical treatment of arterial thrombosis lacks effective targeting and precise drug release capability. In this study, we developed a system for targeted delivery and on-demand release in arterial thrombosis treatment. The carrier was constructed using chitosan (CS) and fucoidan (Fu) through layer-by-layer assembly, with subsequent surface modification using cRGD peptide. Upon encapsulation of urokinase-type plasminogen activator (uPA), the resulting therapeutic drug delivery system, uPA-CS/Fu@cRGD, demonstrated dual-targeting abilities towards P-selectin and αIIbβ3, as well as pH and platelet-responsive release properties...
March 15, 2024: Carbohydrate Polymers
https://read.qxmd.com/read/38197397/nanoparticle-mediated-active-and-passive-drug-targeting-in-oral-squamous-cell-carcinoma-current-trends-and-advances
#18
REVIEW
Jyothsna Manikkath, Aparna Manikkath, Hitesh Lad, Lalitkumar K Vora, Jayesh Mudgal, Rekha R Shenoy, Shashaanka Ashili, Raghu Radhakrishnan
Oral squamous cell carcinoma (OSCC) is an invasive and highly malignant cancer with significant morbidity and mortality. Existing treatments including surgery, chemotherapy and radiation have poor overall survival rates and prognosis. The intended therapeutic effects of chemotherapy are limited by drug resistance, systemic toxicity and adverse effects. This review explores advances in OSCC treatment, with a focus on lipid-based platforms (solid lipid nanoparticles, nanostructured lipid carriers, lipid-polymer hybrids, cubosomes), polymeric nanoparticles, self-assembling nucleoside nanoparticles, dendrimers, magnetic nanovectors, graphene oxide nanostructures, stimuli-responsive nanoparticles, gene therapy, folic acid receptor targeting, gastrin-releasing peptide receptor targeting, fibroblast activation protein targeting, urokinase-type plasminogen activator receptor targeting, biotin receptor targeting and transferrin receptor targeting...
January 10, 2024: Nanomedicine
https://read.qxmd.com/read/38106869/comparison-of-balloon-occluded-thrombolysis-with-catheter-directed-thrombolysis-in-patients-of-budd-chiari-syndrome-with-occluded-direct-intrahepatic-portosystemic-shunt
#19
JOURNAL ARTICLE
Amar Mukund, Tanya Yadav, Satender Pal Singh, Saggere Muralikrishna Shasthry, Rakhi Maiwall, Yashwant Patidar, Shiv Kumar Sarin
Objectives  Direct intrahepatic portosystemic shunt (DIPS) stent placement is an effective treatment for patients with Budd-Chiari syndrome (BCS); however, thrombotic occlusion of DIPS stent remains a cause of concern. The purpose of this study is to describe a novel technique of balloon-occluded-thrombolysis (BOT) for occluded DIPS stent, and compare it with the conventional catheter-directed-thrombolysis (CDT). Methods  In this retrospective study, the hospital database was searched for BCS patients who underwent DIPS revision for thrombotic stent occlusion between January 2015 and February 2021...
January 2024: Indian Journal of Radiology & Imaging
https://read.qxmd.com/read/38063161/immune-activation-mediates-the-association-of-advanced-hepatic-fibrosis-with-adverse-outcomes-in-patients-with-coronary-artery-disease
#20
JOURNAL ARTICLE
Vardhmaan Jain, Anurag Mehta, Terence B Lee, Chang Liu, Nicholas W S Chew, Yi-An Ko, Matthew E Gold, Daniel A Gold, Nishant Vatsa, Shivang R Desai, Jonathan H Kim, Alireza Rahbar, Yazan Haroun, Kiran Ejaz, Salim S Hayek, Mohammad S Siddiqui, Fadi N Salloum, Laurence S Sperling, Arun J Sanyal, Arshed A Quyyumi
BACKGROUND: Literature suggests a bidirectional association between advanced hepatic fibrosis (AHF) and coronary artery disease (CAD). We evaluated the association of AHF with immune activation, systemic inflammation, and adverse outcomes in patients with CAD. METHODS AND RESULTS: A fibrosis-4 index cutoff value ≥2.67 was used to define AHF. Circulating levels of soluble urokinase plasminogen activator receptor and hsCRP (high-sensitivity C-reactive protein) were measured as markers for immune activation and systemic inflammation, respectively...
December 19, 2023: Journal of the American Heart Association
keyword
keyword
120947
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.